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THE direct or indirect influence of certain hormones, e.g. stilboestrol and
testosterone, on the aetiology of malignancy has been well recognised for many
years and has formed the basis of their extensive use in the management of this
disease, particularly in attempting its control in advanced stages. Some of the
cancers ofbreast and ofprostate are good examples oftumours which are hormone
dependent. But the role that the thyroid hormone plays is still uncertain. Beatson
was the first, in 1896, to treat advanced carcinoma ofbreast with thyroid extract
in addition to oophorectomy. Only in the last decade or so the result of a good
deal ofexperimental work and clinical observation has been to suggest that thyroid
secretion plays an important part in the evolution of cancer, particularly ofthe
genitalia and the breast. Loeser (1954) states that the incidence of female breast
carcinoma is far lower in allergic and hyperthyroid conditions than in hypothyroid
women or after thyroidectomy. In his view, it is the low histamine content ofthe
cells of hypothyroid women which increases the tendency to cancer formation.
Spencer (1954), discussing iodine availability in cancer incidence, doubts whether
a low metabolic rate or insufficiency of thyroid substance can be considered as a
primary cause of cancer. He suggests, rather more vaguely, " that thyroid
function (or dysfunction) may be associated with the susceptibility or immunity
to cancer ". Sommers (1955), after examining autopsies of breast cancer cases
and ofabout an equal number ofadult women without cancer, found hyperplastic
modification in one or more endocrine glands and their target organs. A noticeable
exception was the thyroid gland, in which atrophy occurred more commonly
with than without breast cancer. The thyroid atrophy was independent of the
body weight.
Dargent and Mayer (1955), surveying 71 cases of cancer of various sites, have
attempted to demonstrate that thyroid secretion has a definite influence on the
evolution of cancer, and warn that surgical treatment ofgoitre in a case of estab-
lished malignancy should not be undertaken lightly. Dessaive (1956) in both his
experimental work and clinical observations comes to a similar conclusion. From
his study of 13,261 cancers seen in Liege it appears that simple thyroid conditions,
particularly goitre, constitute a favourable element in the formation of cancer.
The effect was found in women much more often than in men, and was especially
noticeable in breast carcinoma. He also found that cancers which develop against
a background of thyroid deficiency have a worse prognosis, and recommends full
investigation before undertaking surgical or other treatment for simple thyroid
disorder, in order to exclude the presence of a cancer which at-that time may beK. SICHER AND J. A. H. WATERHOUSE
quiescent. He postulates the theory that thyroid deficiency creates changes in the
hypophysis which in their turn cause conditions favourable to cancer evolution.
According to him the hyperthyroid state produces a barrier to cancer formation.
In support of this hypothesis he mentions that cancer mortality is very high in
regions where goitre is endemic.
Ellerker (1956) in his survey of 157 women with breast carcinoma found that
7-8 per cent had thyroid anomalies and concurs with other authors that hypo-
thyroidism may be a factor in the formation and spread of cancer. Following this
line of thought Loeser (1958) advises thyroid administration after surgical or
X-ray treatment of the primary tumour which in his opinion can prevent recur-
rence " for a long time, possibly for most of the patient's life ". He treated 56
women with carcinoma ofbreast orgenitalia in this way and claims that recurrence
has been prevented " in the great majority for five years and longer ". He has
lately been injecting solution ofthyroid in and around the tumour, as well as giving
thyroid combinedwithhistidine (Loeser, 1960, personalcommunication). Recently,
Edelstyn, Lyons, and Welbourn (1958) have demonstrated a relationship between
thyroid function and metastatic spread in cancer of the breast: function was
significantly lower in patients with bloodborne metastases than in those with only
local disease.
PRESENT INVESTIGATION
In pursuit of the same line of thought a survey of a group of female patients
suffering from mammary carcinoma was begun in 1956 in Coventry. Thyroid
function tests were carried out either before or at the initial stage oftreatment in
order to discover any dysfunction ofthe thyroid gland.
One hundred and nineteen women with various types ofbreast carcinoma were
investigated by radioactive iodine (1311), and 98 ofthese had their blood cholesterol
estimated also. In all these cases the neoplasm was still localised to the breast
tissue or to regional glandular areas and had no distant metastases. One hundred
and fifteen had simple or radical mastectomy followed by radiotherapy. Only four
patients were found not suitable for surgery and were treated by radiotherapy
alone, but even so it was possible to use a high radical dose. The mean age ofthese
patients was approximately 54 years (Table III). The isotope tracer doses were
given either before commencing or at an early stage ofradiotherapy, to avoid any
alteration in thyroid function due to the radiation itselfwhen treating the supra-
clavicular region. Absorption of iodine in the thyroid gland and excretion of the
isotope in the urine were both measured. Initially the uptake tests were made
using a stand in which the whole of the gland area was viewed by a G 10 Pb
counter through an aperture in a 1 in. lead screen. Later measurements were done
with a " collar " arrangement ofscreened counters around the neck ofthe patient.
In all cases the uptake in the neck was compared with a standard dose contained
in a 25 ml. perspex model of a thyroid gland embedded in a wax model of an
average neck.
The uptake measurements were originally done at 1, 2, 4, and 24 hours but
later the measurement at 1 hour was dropped. For the excretion test the urine
was collected during the periods of 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours,
8-12 hours, 12-24 hours and for low uptake patients 24-48 hours. The criteria for
the results were the same as those in general use for thyroid investigations. These
criteria are summarised in Table I. Cholesterol was estimated by the method of
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Zak et al. (1954) and the present figures were compared with the normal range by
age found by Keys et al. (1950).
TABLE I.-Criteria Adopted in Asses88ment of Thyroid Function by Gland Uptake
and Urinary Excretion of1311
Gland Uptake (% of ingested dose)
Period Normal Hyperthyroid Hypothyroid
1st hour 7-19% 20-50% . 4-11%
2nd hour <25% >25%
4th hour <40% . >40%
24th hour . 13-55% 46-96% 1-10%
Excretion (Urine) (0% of ingested dose)
Period Normal Hyperthyroid Hypothyroid
8-12 hours 3-10% 0-3%
severe mild
6-24 hours 12-38% 0-4; 4v12%
8-24 hours . 7-20% 0.3% . 16-34%
24-48 hours 0-10% 0-4% 8-23%
8-48 hours 9-25%3 .351%
0-24/48 hours 37-70% 4-17% . 60-91%
All except three cases were staged clinically according to the Manchester four-
stage system: in the three cases the clinical information was inadequate to permit
allocation to a stage, and they appear therefore as NIK. Cases were divided
pathologically into the three groups:
Early, where the excised glands were found
histologically to be non-malignant.
Late, where the lymph nodes were found to
be involved.
N/K, where there was no microscopical ex-
amination of the glands.
RESULTS
Of the 98 patients who had serum cholesterol estimations, 18 were considered
to have either high or possibly high readings and 7 cases had either low or possibly
low figures. The range ofserum cholesterol readings was from 128 to 440, the mean
being 259 11 mg. per cent and the standard deviation 58 13. There was a slight,
though not significant, positive correlation between serum cholesterol level and
age. This accords with the trend with age shown by Keys et al. (1950), particularly
for the range of ages included in the present study.
Table II shows the mean, standard deviation, range, and number of cases for
each of two 131J uptake (A, B) and two excretion (C, D) figures. The correlation
coefficient between A and B (0.803) is so high that it is here sufficient to use one of
these readings only, despite the difference in mean. Much the same is true of the
readings C and D for urinary excretion (correlation coefficient _0.772). Only B
therefore was subsequently used for uptake, and C for excretion.
There was a high degree of negative correlation between B and C, as of course
would be expected since an increased uptake implies a reduced excretion. Between
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cholesterol and B or C the correlation was so small as to indicate no sensible
relationship between these readings.
TABLE II. Distribution Within Experimental Series of Certain Uptake and
Excretion Values of1311
131J uptake
Mean
S.D.
Range
(n)
A
17.8K
6 31
2-48
(118)
A =
B =
C =
D=
1311 E
B C
38-78 . 20-0
11-97 6-70
3-65 3-36
(119) (118)
% '3'I Uptake (2nd hour)
00311 Uptake (24th hour)
0 13'I Excretion (6-24 hours)
% '31I Excretion (8-48hours).
xcretion
D
19- 15
8-07
2-45
(86)
The mean values of B (uptake 24th hour), C (excretion 6-24 hours), age, and
cholesterol are given in Table III for each clinical stage, and in Table IV for each
pathological stage, together with the numbers of cases in each group. Here again
there is no very noticeable trend in any of the values shown.
TABLE III.-Mean Values by Clinical Stage of :_131I Uptake 131J Excretion-Age
Serum Cholesterol
Clinical stage
B
C.
Age
(38)
39-1
20-8
53-8
II
(43)
38-0
20-0
53 - 1
III IV
(26) (9)
37-8 44-2
19-3 18-3
55-8 58-0
N/K
(3)
38-0
20-0
55-3
(33)
Cholesterol 249- 6
(mg. %)
(39) (17) (6) (3)
265-2 259-5 238-8 322-7
B = % 1311 Uptake (24th hour).
C = % 131I Excretion (6-24 hour).
Figures in brackets denote the number of cases in each group.
TABLE IV. Mean Values by Pathological Stage of: 131J Uptake 131I Excretion-
Age Serum Cholesterol
Early
(24)
38-4
20-3
.-50 7
(23)
247-9
Pathological stage
Late N/K
(57) (38)
39-3 38-0
19-2 21-2
54-2 57 0
(43)
257 9
(32)
268- 8
B % 131I Uptake (24th hour).
C = % 1311 Excretion (6-24 hour).
Figures in brackets denote the number of cases in each group.
B
C
Age
Cholesterol
(mg. %)
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In the case of gland uptake, our experience (24th hour) corresponds very
closely with that of Edelstyn et al. (1958) for their group with local disease only.
Their mean value (37'6 per cent) and ours (39 1 per cent) are virtually indistin-
guishable, and the standard deviations (9.77 and 11-78) also accord well together.
Our range (3-65) is more extensive than theirs (25-65) as might be expected in a
sample nearly 5 times as large (119 against 26) ; only 4 of our 119, however, are
below 20 per cent.
TABLE V. Distribution of T-index (Fraser et al., 1953)
Range %
Very Low . . ( 12l) 4 5
Low (<2 8) 8 10
NORMAL (<12-8) 68 82
Probably high . (< 17 4) 1 1
High . (>17-4) 2 2
83* 100
* For various reasons it was not possible to obtain a T-index for all our patients.
For urinary excretion we have calculated the T-index of Fraser et al. (1953)
on 83 ofourpatients. Table V shows their distribution in terms ofthe five groupings
used by Fraser. We have 82 per cent within his Normal range, 3 per cent above it,
and 15 per cent below. Ofthe latter, 4 (5 per cent) only are within his Very Low or
myxoedematous group. Before the T-index was computed, these four patients
were classified clinically. In two, myxoedema was mentioned, and the other two
were described as " low normals ". Ofthe 8 in the next group, three were described
as possibly myxoedematous, and the remaining five normal. The three classified
above Normal in Fraser's grouping were all described as " hyper ", though two of
them were only mildly so. Thus our results show a slight bias towards hypo-
function in their distribution, although the mean value works out at 6-3, due to
the inclusion of the High group, one ofwhich had a T-value of 90.
From the diagram published in their paper, Edelstyn et al. (1958) show an
even greater bias towards hypofunction, fortheirgroup with local disease only the
group most nearly comparable with our own. Of their 23 cases, 17 are in the
Normal group, 4 in the Low, and 2 in the Very Low, making 26 per cent below
Fraser's lower extremity of the Normal group. Taken in conjunction with our
more equivocal findings, it is perhaps suggestive ofa reduction in thyroid function,
manifested in patients with breast cancer, even when confined to local spread only.
However, neither Edelstyn et al. nor we, for similar reasons, have studied a control
group of individuals without cancer.
DISCUSSION
In our series, where the growth was still localised to breast tissue or to regional
glands, without distant metastases, there is no apparent association with thyroid
dysfunction. This is in accord with the main findings of Edelstyn et al. (1958) in
cases of local disease. Indeed, we might on this evidence hazard the observation
that thyroid dysfunction plays little part in the primary aetiology of mammary
cancer, apart from the slight bias towards hypofunction demonstrated above.
The interest now focusses on the role of the thyroid in metastatic spread of the
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disease, and on whether the association, reported for instance by Edelstyn et al.
(1958), between thyroid dysfunction and blood borne metastases is a consequential
or a concomitant one. Does a reduced thyroid output in some way facilitate
metastatic growth, or does the presence of an active growth depress the thyroid,
either directly or through the pituitary ? Alternatively both manifestations may
be due to some third factor not yet clearly identified. The importance, both
therapeutic and theoretical, ofelucidating this relationship demands a programme
ofdetailed observation and appraisal. Tests ofthyroid function should be made at
the outset, before treatment is given-certainly before radiotherapy which might
well disturb the pattern. Thereafter a careful follow-through study is necessary
to determine the subsequent fate in terms both ofmetastatic spread and ofthyroid
function. Only by such prospective and continuing studies can we hope to obtain
an answer to the fundamental question of " which comes first? ". The material
we present here cannot yet attempt to provide an answer: it is only in a very early
stage. We believe however that the basic question is of sufficient importance to
justify such a preliminary communication, if only to stimulate the collection of
similar data on a larger scale. Our own cases have not yet been followed for more
than three to four years. We shall ofcourse keep a careful watch on them in order
to assess progress and survival according to their thyroid function.
SUMMARY
Thyroid function was determined by means of radioactive iodine uptake and
urinary excretion in a series of cases of breast cancer localised to the breast or
regional glands. Ninety-eight of the series of 119 had also estimations of blood
cholesterol. Although there appeared to be a slight bias towards hypothyroid
function, no evidence ofstatistically significant thyroid dysfunction was obtained.
All these cases are being followed to determine whether an association exists
between thyroid dysfunction and metastatic spread.
We wish to thank Mr. J. D. F. Williams, principal physicist at the Coventry
andWarwickshire Hospital, forundertaking theiodine studies; Mr. R. W. Richard-
son, seniorbiochemist ofthe same Hospital, who was responsible forthe cholesterol
estimations; and Mrs. Valerie Evans for much secretarial and computational
assistance.
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